DISCONTINUATION RATES FOLLOWING A SWITCH FROM A REFERENCE TO A BIOSIMILAR BIOLOGIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS.

Natália Sousa Freitas Queiroz,Rogerio Saad-Hossne,Renata de Sá Brito FrÓes,Francisco Guilherme Cancela E Penna, Stefania Burjack Gabriel, Adalberta Lima Martins,Fabio Vieira Teixeira

Arquivos de gastroenterologia（2020）

引用 10|浏览0

暂无评分

摘要

Discontinuation rates following a switch to a biosimilar in patients with IBD increase over time. However, it was not possible to confirm the nocebo effect as a reason for discontinuation. Therefore, long-term studies evaluating the use of biosimilars to monitor adverse events and potential nocebo effects in post-marketing surveillance are still needed.

查看译文

关键词

Inflammatory bowel diseases, drug therapy,Biological products,Therapeutic equivalency,Biosimilar pharmaceuticals,Review

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要